Sera Prognostics Stock (NASDAQ:SERA)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$2.35

52W Range

$1.37 - $4.09

50D Avg

$2.18

200D Avg

$2.85

Market Cap

$87.81M

Avg Vol (3M)

$57.65K

Beta

1.06

Div Yield

SERA Company Profile

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Jul 15, 2021

Website

SERA Performance

SERA Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$81.00K	$77.00K	$306.00K
Operating Income	$-36.50M	$-36.63M	$-39.82M
Net Income	$-31.93M	$-32.90M	$-36.24M
EBITDA	$-36.50M	$-32.04M	$-35.29M
Basic EPS	$-0.67	$-0.99	$-1.16
Diluted EPS	$-0.67	$-0.99	$-1.16

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Mar 18, 26 | 5:00 PM

Q3 25Nov 13, 25 | 5:00 PM

Q2 25Aug 07, 25 | 5:00 PM

Peer Comparison

Ticker	Company
RPID	Rapid Micro Biosystems, Inc.
SRZN	Surrozen, Inc.
TVGN	Tevogen Bio Holdings Inc.
APYX	Apyx Medical Corporation
HURA	TuHURA Biosciences, Inc.
CGTX	Cognition Therapeutics, Inc.
ONCY	Oncolytics Biotech Inc.
STSS	Sharps Technology, Inc.
LUCD	Lucid Diagnostics Inc.
ATOS	Atossa Therapeutics, Inc.